Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
暂无分享,去创建一个
Maria Werner-Wasik | Walter J Curran | W. Curran | R. Paulus | R. Byhardt | Rebecca Paulus | Roger Byhardt | M. Werner-Wasik
[1] C. Freeman,et al. 193 Does the RTOG/EORTC scoring schema (RESS) truly reflect the late radiation morbidity in lung cancer patients? , 2005 .
[2] Issam El-Naqa,et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. , 2004, International journal of radiation oncology, biology, physics.
[3] J. Blay,et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Rubin,et al. Morphological correlates of fractionated radiation of the mouse lung: early and late effects. , 1994, International journal of radiation oncology, biology, physics.
[5] T. Pajak,et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. , 1993, International journal of radiation oncology, biology, physics.
[6] J. Fowler,et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. , 2010, International journal of radiation oncology, biology, physics.
[7] Jeffrey D Bradley,et al. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[8] D. Gandara,et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Stephens,et al. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Joos V Lebesque,et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. , 2003, International journal of radiation oncology, biology, physics.
[11] W. Curran,et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. , 1995, Journal of the National Cancer Institute.
[12] W. Curran,et al. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410 , 2000 .
[13] H. Choy,et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Choy,et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). , 2000, International journal of radiation oncology, biology, physics.
[15] D. Ettinger,et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90‐15 , 1995, Cancer.
[16] B. Jeremic,et al. Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. , 1998, International journal of radiation oncology, biology, physics.
[17] W. Curran,et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.
[18] Michael Lock,et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] P. Maguire,et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.
[20] R. Komaki,et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.
[21] Zhongxing Liao,et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). , 2005, International journal of radiation oncology, biology, physics.
[22] R K Ten Haken,et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.
[23] Tae Hyun Kim,et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[24] M. Roach,et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. , 1999, International journal of radiation oncology, biology, physics.
[25] Jose Belderbos,et al. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] J A Purdy,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.
[27] K. Kelly,et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). , 2006, Clinical lung cancer.
[28] R. Mohan,et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.
[29] Lawrence B Marks,et al. Dosimetric and clinical predictors for radiation-induced esophageal injury. , 2005, International journal of radiation oncology, biology, physics.
[30] J D Kalbfleisch,et al. Hazard rate models with covariates. , 1979, Biometrics.
[31] R. Clough,et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. , 2001, International journal of radiation oncology, biology, physics.
[32] R. Komaki,et al. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. , 1998, International journal of radiation oncology, biology, physics.
[33] W. Curran,et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Jeffrey Bradley,et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.
[35] R. Komaki,et al. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. , 1998, International journal of radiation oncology, biology, physics.
[36] D. Ettinger,et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. , 2002, International journal of radiation oncology, biology, physics.